Crinetics Pharmaceuticals, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

Checking your notes…

(in thousands, except per share data)

	Three months ended June 30,		Six months ended June 30,
	2025	2024	2025	2024
Revenues	$1,031	$399	$1,392	$1,039
Operating expenses:
Research and development	80,301	58,344	156,541	111,685
Selling, general and administrative	49,842	24,838	85,368	45,666
Total operating expenses	130,143	83,182	241,909	157,351
Loss from operations	(129,112)	(82,783)	(240,517)	(156,312)
Other income (expense):
Interest income	13,455	8,741	28,289	16,061
Other income (expense), net	20	(13)	(183)	(264)
Total other income, net	13,475	8,728	28,106	15,797
Loss before equity method investment	(115,637)	(74,055)	(212,411)	(140,515)
Loss on equity method investment	—	—	—	(470)
Net loss	$(115,637)	$(74,055)	$(212,411)	$(140,985)
Net loss per share:
Net loss per share — basic and diluted	$(1.23)	$(0.94)	$(2.27)	$(1.86)
Weighted average shares — basic and diluted	93,791	79,008	93,448	75,690
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities	$(347)	$(340)	$686	$(1,167)
Unrealized loss on foreign currency	(34)	—	(28)	—
Total other comprehensive income (loss)	(381)	(340)	658	(1,167)
Comprehensive loss	$(116,018)	$(74,395)	$(211,753)	$(142,152)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.